GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

Share

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.

Leuven, BELGIUM – 27 March, 2024 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 1,630,434,782 new ordinary shares on March 25, 2024, for a total amount of EUR 150,000 pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 9,014,821,287 outstanding ordinary shares carrying voting rights (compared to 7,384,386,505 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
84,356,161.32
  • Total number of securities with voting rights (all ordinary shares)
9,014,821,287
  • Total number of ordinary shares (= denominator)
9,014,821,287
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued (excluding any shares resulting (a) from the potential conversion of any convertibles bonds issued on December 20, 2021 to the benefit of Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. or (b) from the exercise of any subscription rights issued by the Company to the benefits of employees, consultants or directors of the Company (as they are both currently significantly out-of-the-money):


  • 304 convertible bonds issued on March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October 20, 2023, October 24, 2023, November 15, 2023 and November 15, 2023, January 9, 2024, February 2, 2024 and March 4, 2024, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023, as amended on September 10, 2023 and December 22, 2023.

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Please contact for additional information:

Oxurion NV
Pascal Ghoson
Chief Executive Officer
pascal.ghoson@oxurion.com

Backstage Communication
Jurgen Vluijmans
Partner
jurgen@backstagecom.be



1 Press release Oxurion, 02/03/2023

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

CNH NAMES GERRIT MARX AS CEO: Mr. Marx returns to CNH from Iveco Group, succeeding Scott W. Wine who has decided to leave the Company having successfully overseen the delivery of the 2021 Business Plan21.4.2024 18:21:00 CEST | Press release

CNH NAMES GERRIT MARX AS CEO Mr. Marx returns to CNH from Iveco Group, succeeding Scott W. Wine who has decided to leave the Company having successfully overseen the delivery of the 2021 Business Plan Basildon, April 21, 2024 CNH Industrial N.V. (NYSE:CNHI) announces the appointment of Gerrit Marx to the role of CEO effective July 1, 2024. He succeeds Scott Wine, whose request to leave the Company at the end of the current three-year business plan cycle to pursue other interests, has been accepted by the Board. Mr. Marx rejoins CNH from Iveco Group where as CEO he has led that company’s drive into a new era of connectivity, integrating the latest digital and data technologies with Iveco’s product offering. He has also chaired Iveco’s powertrain business overseeing its transition to alternative propulsion systems. Prior to first joining CNH in January 2019, Mr. Marx worked for 20 years in senior roles at McKinsey, Daimler Trucks, and Bain Capital, living in Brazil, China, Europe and Jap

Olof Persson to replace Gerrit Marx as CEO of Iveco Group starting from July 202421.4.2024 18:15:00 CEST | Press release

Turin, 21st April 2024. The Board of Iveco Group N.V. (EXM: IVG) (or “the Group”) announces that Olof Persson will succeed Gerrit Marx as Group CEO when the latter leaves the Group to take up his appointment as the CEO of CNH Industrial N.V. (NYSE: CNHI) on 1st July 2024. Mr. Persson, who is currently an Iveco Group Board Independent Director, will step in to the role of CEO, having been closely involved in the development of the Group’s plans as presented at our recent Capital Markets Day. Suzanne Heywood, Chair of Iveco Group commented: “On behalf of everyone at Iveco Group I’d like to thank Gerrit for his energetic and successful leadership over the past two and half years and wish him every success in his new role. We are fortunate indeed that Olof, with his wealth of relevant industry experience, will step in as CEO and provide a guarantee of continuity in execution of the plans we presented in March.” Olof Persson said: “As a Board member I have been greatly impressed by the enti

Conferize A/S offentliggør aktieemission med fortegningsret for eksisterende aktionærer21.4.2024 17:48:46 CEST | pressemeddelelse

Selskabsmeddelelse nr. 11/2024 København, den 21. april 2024 IKKE TIL OFFENTLIGGØRELSE I USA, CANADA, AUSTRALIEN, JAPAN ELLER NOGEN ANDEN JURISDIKTION, HVOR FREMSÆTTELSE AF UDBUDDET VILLE UDGØRE EN OVERTRÆDELSE AF LOVGIVNINGEN I DEN PÅGÆLDENDE JURISDIKTION. Conferize A/S offentliggør aktieemission med fortegningsret for eksisterende aktionærer Bestyrelsen i Conferize A/S („Conferize“ eller „Selskabet“) har i dag besluttet at forhøje Selskabets aktiekapital med minimum nominelt DKK 2.000.000,00 og op til nominelt DKK 5.878.705,65 fordelt på minimum 200.000.000 stk. og op til 587.870.565 stk. nye aktier a nominelt DKK 0,01 („Udbudte Aktier“) med en tegningskurs på DKK 0,01 pr. Udbudt Aktie („Tegningskursen“) med fortegningsret for Selskabets eksisterende aktionærer i forholdet 1:3 („Udbuddet“). Brutto provenuet ved en fuldtegnet emission forventes at udgøre DKK 5,9 mio. Minimum udbuddet på DKK 2,0 mio. er garanteret gennem forhånds- og garantitilsagn. Selskabet har modtaget bindende forh

Correction to Company announcement – No. 23 / 202419.4.2024 22:20:51 CEST | Press release

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons it was reported that member of the management, Henriette Wennicke, was allocated a total of 8,008 restricted stock units with a total value of DKK 9,577,568.00. The correct number was a total of 8,008 restricted stock units with a total value of DKK 4,788,784.00. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10

Nokia Corporation: Repurchase of own shares on 19.04.202419.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 19 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 19.04.2024 Espoo, Finland – On 19 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL430,8933.30CEUX--BATE--AQEU--TQEX--Total430,8933.30 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

HiddenA line styled icon from Orion Icon Library.Eye